Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder

Ralf W. Dittmann (Lead / Corresponding author), Esther Cardo, Peter Nagy, Colleen S. Anderson, Ben Adeyi, Beatriz Caballero, Paul Hodgkins, Richard Civil, David R. Coghill

    Research output: Contribution to journalArticle

    12 Citations (Scopus)
    123 Downloads (Pure)

    Abstract

    A secondary objective of this head-to-head study of lisdexamfetamine dimesylate (LDX) and atomoxetine (ATX) was to assess treatment response rates in children and adolescents with attention-deficit hyperactivity disorder (ADHD) and an inadequate response to methylphenidate (MPH). The primary efficacy and safety outcomes of the study, SPD489-317 (ClinicalTrials.gov NCT01106430), have been published previously.
    Original languageEnglish
    Pages (from-to)1059-1069
    Number of pages11
    JournalCNS Drugs
    Volume28
    Issue number11
    DOIs
    Publication statusPublished - Nov 2014

    Fingerprint Dive into the research topics of 'Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder'. Together they form a unique fingerprint.

  • Cite this